Erkki Ruoslahti, MD, PhD
Erkki Ruoslahti, MD, PhD, was appointed to the Lisata Board in September 2022 as part of the merger of Lisata with Cend Therapeutics, Inc., where Dr. Ruoslahti served as Chairman of the Board of Directors. He earned his M.D. and Ph.D. from the University of Helsinki in Finland in 1967. After postdoctoral training at the California Institute of Technology, he held various academic appointments with the University of Helsinki and the University of Turku in Finland and City of Hope National Medical Center in Duarte, California. He joined the Sanford-Burnham Institute for Medical Research in 1979 and served as its President from 1989-2002. Dr. Ruoslahti cofounded the Center for Nanomedicine and was a distinguished professor at University of California Santa Barbara in Biological Sciences from 2005-2015. In addition to the 2022 Albert Lasker Basic Medical Research Award, Dr. Ruoslahti’s honors include elected membership to the U.S. National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the European Molecular Biology Organization; and receipt of the Japan Prize, the Gairdner Foundation International Award, the G.H.A. Clowes Award, the Robert J. and Claire Pasarow Foundation Award, and the Jacobaeus International Prize. On the entrepreneurial side, Dr. Ruoslahti is an inventor of about 150 patents and a fellow of the National Academy of Inventors. He has founded several biotech companies and served on the board of directors of two publicly traded companies in addition to Lisata.